List of contents
Jakarta, clubnet Indonesia
–
Facts of vaccine
cancer
Russia was later discussed after the country announced the success of the initial clinical trials
vaccine
Enteromix.This MRNA -based vaccine records a surprising result, which is 100 percent effective shrinking tumors without causing serious side effects.
This announcement was made in an international forum at St.Petersburg in 2025 and immediately became the spotlight of the world.The reason is, this finding can be a big breakthrough in efforts to find cancer therapy that is safer, more effective, and personal for patients.
Enteromix’s success is not only important for Russia, but also brings new hopes to millions of cancer patients worldwide.With a personal approach and the latest technology, this vaccine has the potential to change the medical way of dealing with diseases that have been known to be difficult to cure.
Here are the facts of Russian cancer vaccine that you need to know, launch
NDTV
:
1. 100 percent effectiveness in the initial test
In the first stage of clinical trials involving 48 colorectal cancer patients, enteromix succeeded in showing perfect results: all patients experience tumor shrinkage.There are no serious side effects reported, making this vaccine the main highlight of the medical world.
2. Use MRNA technology such as the Covid-19 vaccine
Enteromix was developed using MRNA technology, a platform that was also used to make a COVID-19 vaccine.The difference is, this time MRNA is specially programmed so that the immune system can recognize and destroy cancer cells.
3. Personal for each patient
Unlike the same conventional treatment for everyone, enteromix is designed personal.This vaccine is made based on the genetic map of each patient’s tumor, so it is more targeted and minimal side effects than chemotherapy.
4. Developed by a prominent Russian research institution
Enteromix research was conducted by the National Medical Research Radiological Center in collaboration with the Engelhardt Institute of Molecular Biology.Announcement of clinical trial results was delivered in an international forum in St.Petersburg in 2025.
5. Still need further tests
Although the initial results are very promising, experts emphasize that further research is still needed.Long -term effectiveness, production costs, and challenges of MRNA -based personal vaccine distribution are still large homework.
The fact of this Russian cancer vaccine confirms that the medical world is entering a new phase in the war against cancer.If the advanced test is successful, Enteromix can open the way to more personal, effective, and minimal side effects therapy.
(tis/tis)
[Gambas: clubnet video]
Read More: Untung365 Alternative Login Site Loan News Information |Iphone 17 Series Leaks Ahead of …
Read More: RI Students in the Netherlands died while accompanying officials to Austria
